干扰素与静脉丙球联合治疗新生儿病毒性肺炎临床效果研究

目的探讨α-2b干扰素与静脉丙球(IVIG)联合治疗新生儿病毒性肺炎的疗效及其安全性。方法将95例病毒性肺炎患儿分为治疗组45例和对照组50例,除常规治疗外,治疗组加用α-2b干扰素与静脉丙球,对照组加用病毒唑治疗。结果两组退热时间、咳嗽、气促及
音消失时间比较差异均有统计学意义(P<0.05)。治疗组治愈率为55.6%,对照组为34.0%,两组比较差异有统计学意义(P<0.05)。治疗组总有效率为93.3%,对照组为62.0%,两组比较差异有统计学意义(P<0.01)。结论α-2b干扰素与静脉丙球联合治疗新生儿病毒性肺炎疗效优于病毒唑,未见明显不良反应,值得临床推广。

Objective To study the treatment effect of α-2b interferon and IVIG on viral pneumonia of neonate. Methods 95 neonates with viral pneumonia were divided into 2 groups. The treatment group was treated with interferon plus IVIG and the control group was treated with ribavirin. Results showed that the average treated course of experimental group On defervescing,coughing, panting and accelerating the disappearance of lung moist crackles was shorted significantly than that of control group（P〈0.05 ）. The cure rate and the effectual rate of the treatment group were both higher significantly than the control group（P〈0.01 ）.Conclusion This suggest that ct-2b interferon and IVIG may improve immunological function of body, it is effective to treat viral pneumonia of neonate.